Jia Liu: Rise of Proteomics as Biomarkers for Precision Oncology
Jia Liu, Translational Lead of The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Claudin 18.2 ADCs and the rise of proteomics as biomarkers for precision oncology
Delighting to share our publication in Nature Portfolio Nature Medicine of Phase 1 results of a novel Claudin 18.2 targeted, topoisomerase payload ADC IBI343 on behalf of coauthors from and in collaboration with Innovent Biologics.
Claudin 18.2 is an exciting therapeutic and its lineage-associated aberrant expression in gastric/gastro-oesophageal cancers (and pancreatic cancers) has heralded an explosion of treatments including ADCs, CAR-T and monoclonal antibodies including FDA-approved zolbetuximab.
Key findings from our trial:
-127 heavily pretreated G/GOJ patients enrolled (19 escalation; 108 expansion)
-RP2D 6mg/kg, 66% G3+ TRAEs, nausea (an on-target side effect) G3 was only 1.7%
-No interstitial lung disease, related to Fc silenced design of the antibody, with no ADCC
ORR 29% and mPFS 5.5 months in CLDN18.2-high (2+/3+ ≥ 75%) Gastric/GEJ adenocarcinoma
Claudin 18.2 now joins HER2, PD-L1 and (emerging target FGFR2b) as the number of proteomic biomarkers required to stratify precision oncology in gastric/GEJ cancers continues to increase. no longer sufficient!
Novel quantitative proteomic assays that simultaneously profile multiple targets are urgently needed!
Read full article.
To all trials staff The Kinghorn Cancer Centre, St Vincent’s Health Network Sydney, patients and referring clinicians for support and contribution to the trial and Megan Barnet for being my upper GI partner in crime at ESMOGI24 when this was first presented.
As I prepare to speak at ESMOTAT Asia25 in Hong Kong this week, I hope this serves as example of fruitful collaboration that is possible between Australian Phase 1 trial sites with biopharma and investigators across Asia-Pacific.
Reach out if you are here to discuss opportunities to collaborate!”
Title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
Authors: Jia Liu, Jianwei Yang, Yuping Sun, Jifang Gong, Jinbo Yue, Yueyin Pan, Meili Sun, Rongfeng Song, Xiuying Xiao, Andrea Tazbirkova, Jian Ruan, Zhenyang Liu, Zimin Liu, Zhihua Li, Lili Sheng, Yanru Qin, Jieer Ying, Xianjun Yu, Jian Zhang, Yiping Mou, Chuangxin Lu, Ping Chen, Suyi Li, Jie Li, Xiujuan Qu, Ting Deng, Juan Du, Aiping Zhou, Enxiao Li, Xianglin Yuan, Xinjun Liang, Weiming Yu, Michelle Morris, Yang Luo, Xin Zhao, Yingmei Guo, Hui Zhou, Lin Shen
More posts featuring Precision Oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023